#Bullous Pemphigoid Market Trend | Explore Tumblr posts and blogs

colinwilson11 · 3 months ago

Text

Digitalization Will Propel The Bullous Pemphigoid Market Growth Owing To Increased Diagnosis Accuracy

The Bullous Pemphigoid Market involves treating a rare autoimmune disease wherein the immune system attacks the skin and mucous membranes resulting in large fluid-filled blisters and vesicles on the skin and mucosal membrane. Bullous Pemphigoid primarily affects the elderly population above the age of 60 and leads to extensive itching and pain. The main treatment modalities involve immunomodulatory medications such as corticosteroids, anti-inflammatory drugs, and immunosuppressive medications to ease symptoms.

The Bullous Pemphigoid Market is estimated to be valued at US$ 1.4 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024-2031.

Key players operating in the Bullous Pemphigoid market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, and Roche. These companies offer a range of treatment options from oral and topical corticosteroids to immunosuppressive therapies. The increasing geriatric population prone to developing bullous pemphigoid coupled with rising awareness regarding the condition is expected to drive the growth of the market. Additionally, advancements in diagnosis facilitated by digital imaging technologies assist in prompt diagnosis and treatment of the condition, thereby improving treatment outcomes.

Key Takeaways

Key players analysis: Key players operating in the Bullous Pemphigoid market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, and Roche. GlaxoSmithKline leads the market with drugs including Rituximab and Benlysta.

Growing demand: The growing geriatric population accounted for a major share of the bullous pemphigoid patient pool. According to the WHO, the number of people aged 60 years and older is expected to double by 2050. This significantly drives the demand for bullous pemphigoid treatment.

Technological advancement: Advancements in digital imaging and teledermatology allow accurate diagnosis of bullous pemphigoid through visualization of skin lesions via smartphones and teleconsultation. This enables early intervention and superior management of the condition.

Market Trends

Combination therapies: There is a growing trend of using drug combinations as opposed to monotherapies to effectively manage bullous pemphigoid. Popular combinations involve corticosteroids with immunosuppressants.

Targeted biologic agents: Novel targeted biologic agents aimed at specific antibodies and immune pathways involved in bullous pemphigoid show promise. Drugs like Rituximab, Inebilizumab, and Eculizumab are being evaluated for efficacy and safety.

Market Opportunities

Emerging economies: Countries in Asia Pacific and Latin America present lucrative opportunities for bullous pemphigoid treatment providers owing to growing medical needs of their aging population and economic expansion.

Online consultations: Telehealth and e-pharmacy platforms allow people to remotely access bullous pemphigoid specialists and medication, thereby overcoming distance barriers. This increases access to care.

Impact Of COVID-19 On Bullous Pemphigoid Market Growth

The COVID-19 pandemic has significantly impacted the growth of the bullous pemphigoid market. During the initial phases of the pandemic between 2020-21, the market witnessed a decline in growth rate owing to lockdowns imposed across various countries. This led to postponement of non-essential dermatological procedures and treatments. Patients also avoided visiting healthcare facilities fearing exposure to the virus. As a result, diagnosis and treatment rates for bullous pemphigoid reduced considerably during this period.

However, with lifting of lockdowns and rollout of vaccination drives globally, the market has started recovering post 2021. Increased awareness about the autoimmune disorder and availability of effective treatment options are supporting the growth trajectory. Various initiatives undertaken by key market players to ensure uninterrupted supply of drugs and therapies have also boosted market revenues. For instance, companies streamlined their production and distribution channels to meet the rising demand. Teleconsultations further aided continued care for patients during lockdowns.

Going forward, the bullous pemphigoid market is expected to witness robust expansion supported by ageing population prone to developing the condition. Moreover, rapid advancements in biologics and targeted therapies will expand treatment options. Players are investing heavily in R&D to develop novel pipeline drugs. Favorable regulatory environment and reimbursement policies will augment market access. Widespread vaccination drives and resumption of normal healthcare activities will further accelerate market growth in the coming years.

Europe holds the largest share of bullous pemphigoid market in terms of value owing to sizeable patient pool and high treatment uptake. North America follows Europe in terms of revenue generation led by rising disease prevalence and advanced healthcare infrastructure. Asia Pacific is recognized as the fastest growing regional market and will continue exhibiting strong growth momentum through 2031. This can be attributed to improving access to diagnosis and treatment options due to expanding healthcare expenditure in countries like China and India.

Geographical Regions With Highest Bullous Pemphigoid Market Value

North America accounts for the largest share of the Bullous Pemphigoid Market value-wise. The region is estimated to hold over 35% revenue share of the overall market in 2024 led by strong presence of leading pharmaceutical companies in US and Canada. Increased focus on research into novel treatment options along with supportive reimbursement policies are driving the growth of the North America bullous pemphigoid market.

Europe holds the second largest value share globally on account of rising burden of the autoimmune disorder due to aging population. Countries like Germany, UK, France, Italy are major revenue generators for Europe bullous pemphigoid market. High healthcare expenditure and availability of affordable treatments make Europe an attractive regional market.

Geographical Region Witnessing Fastest Growth In Bullous Pemphigoid Market

Asia Pacific region has emerged as the fastest growing geographical market for bullous pemphigoid globally. The Asia Pacific bullous pemphigoid market is projected to expand at a CAGR of over 12% during 2024-2031. Factors such as growing geriatric demographic, increasing medical awareness regarding bullous pemphigoid diagnosis and management, rising healthcare spending, and improving access to advanced drugs are fueling the market growth. Countries like India, China, Japan, and South Korea are expected to drive substantial revenues for bullous pemphigoid treatment manufacturers within Asia Pacific market.

Get more insights on this topic: https://www.ukwebwire.com/bullous-pemphigoid-market-growth-to-be-fueled-by-advancements-in-targeted-therapies/

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

What Are The Key Data Covered In This Bullous Pemphigoid Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Bullous Pemphigoid Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Bullous Pemphigoid Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Bullous Pemphigoid Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Bullous Pemphigoid Market vendors

FAQ’s

Q.1 What are the main factors influencing the Bullous Pemphigoid Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Bullous Pemphigoid Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Bullous Pemphigoid Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

#Bullous Pemphigoid Market Trend #Bullous Pemphigoid Market Size #Bullous Pemphigoid Market Information #Bullous Pemphigoid Market Analysis #Bullous Pemphigoid Market Demand

0 notes

mrfrblog12 · 8 days ago

Link

#Bullous Pemphigoid Treatment Market Size Bullous Pemphigoid Treatment Market Share Bullous Pemphigoid Treatment Market Growth

0 notes

ibommamovies · 8 days ago

Link

#Bullous Pemphigoid Treatment Market Size Bullous Pemphigoid Treatment Market Share Bullous Pemphigoid Treatment Market Growth

0 notes

chemicalsmaterial · 3 years ago

Photo

https://www.databridgemarketresearch.com/reports/global-pemphigoid-drug-market

Global Pemphigoid Drug Market, By Type (Bullous Pemphigoid, Cicatricial Pemphigoid, Pemphigoid Gestationis), Medication Type (Corticosteroids, Anti-Biotics, Steroid-Sparing Immunosuppressant Drugs, Others), Route of Administration (Oral, Injectable and Topical), Distribution Channel (Online Pharmacy, Direct Tenders, Retailers, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

#pemphigoid

0 notes

globalaircraft · 3 years ago

Text

#pemphigoid drug

0 notes

timesnest · 4 years ago

Photo

Bullous Pemphigoid Treatment Market Size, Share, Trends and Analysis 2020 to 2026| Pfizer, Aqua Pharmaceuticals, Sirius Laboratories – re:Jerusalem

0 notes

coolluminaryland-blog1 · 6 years ago

Text

Bullous Pemphigoid Treatment Market : Outlook 2020 , Global Opportunity & Growth Analysis

Bullous pemphigoid is a rare autoimmune inflammatory skin disease that causes large, fluid-filled blisters on the skin. It is characterized by urticarial lesions, blistering, and itching. Generally, these develop on areas such as the upper thighs or armpits and the lower abdomen. Bullous pemphigoid generally occurs when the body’s immune system attacks a thin layer of the tissue below the outer layer of the skin. It can occur in any age group including kids. Most often, it affects elderly individuals.

Redness and itching of the skin is the most common sign and symptom of bullous pemphigoid. It occurs on the mucous membranes such as lips, mouth, nasal passages. The exact cause of the disease is not known. According to studies conducted by PubMed, bullous pemphigoid can be caused by certain medications (such as durvalumab, nivolumab), ultraviolet light therapy, or radiation therapy. Also, psoriasis, lichen planus, diabetes mellitus, rheumatoid arthritis, and ulcerative colitis play a role in the development of bullous pemphigoid.

Read Report Overview: https://www.transparencymarketresearch.com/bullous-pemphigoid-treatment-market.html

Dermatologist can diagnose bullous pemphigoid based on the patient’s medical history as well as certain tests. A common diagnostic test for bullous pemphigoid is skin biopsy. Enzyme-linked immunosorbent assay (ELISA) can be used to detect presence of bullous pemphigoid autoantibodies in the serum.

Rise in the prevalence of bullous pemphigoid across the world is anticipated to drive the global bullous pemphigoid treatment market during the forecast period. Increasing government funding for rare disorders drug is also expected to propel the global market in the near future. However, shortage of health care experts in Latin America and Middle East & Africa hampers the bullous pemphigoid treatment market in these regions. Nevertheless, increase in government funding for diagnostic procedures is likely to augment the bullous pemphigoid treatment market in the next few years. Organizations supporting the treatment of the disease across the world include International Pemphigus & Pemphigoid Foundation, American Autoimmune & Related Diseases Association, Inc., Australasian Blistering Diseases Foundation, NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases, and Genetic and Rare Diseases (GARD) Information Center.

The global bullous pemphigoid treatment market can be segmented based on drug, end-user, and region. In terms of drug, the bullous pemphigoid treatment market can be segmented into corticosteroids, anti-inflammatory drugs and immunosuppressant drugs or biologics. Clobetasol is the common topical corticosteroid used for the treatment of bullous pemphigoid. Immunosuppressants such as azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, and cyclosporine are applied for the treatment of the disease. Rituximab and omalizumab are most common biologics employed for the treatment of bullous pemphigoid.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=56178

In terms of end-user, the global bullous pemphigoid treatment market can be divided into hospitals and special clinics. The hospitals segment held a major share of the market in 2017.

Based on region, the global bullous pemphigoid treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America accounted for a leading share of the global market in 2017, followed by Europe and Asia Pacific. The U.S. held a significant share of the market in North America, in terms of revenue, in 2017. The market in Asia Pacific is expanding rapidly, due to increase in the number of patients suffering from the disease. Better health care infrastructure, economic growth, rise in the number of insurance payers, expanding and developing private health care sector, and increase in awareness among people about treatment of bullous pemphigoid in Asia Pacific are expected to propel the bullous pemphigoid treatment market in the region in the next few years. The bullous pemphigoid treatment market in Latin America and Middle East & Africa is projected to expand at a moderate growth rate from 2018 to 2026.

Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=56178

Key players operating in the global bullous pemphigoid treatment market are Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Novartis AG, Baxter, and F. Hoffmann-La Roche Ltd.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Transparency Market Research 90 State Street, Suite 700, Albany NY – 12207 United States Tel: +1-518-618-1030 USA – Canada Toll Free 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com/

0 notes

healthy-insights · 7 years ago

Text

Bullous Pemphigoid treatment Market Analysis and Key Trends 2025

Bullous pemphigoid is a chronic, inflammatory skin disease that involves the formation of blisters. The bullous may be of different forms such as generalized, vesicular, vegetative, Urticarial, Nodular, Acral or infant forms. The disease is not gender biased and can also occur in younger adults but is rare in infants. The blood blister due to bullous pemphigoid occur in people aging above 70 years. Bullous pemphigoid occurs when the immune system outbreaks a thin layer of tissue below the outer layer of skin. It is more prevalent in patients suffering from dermatitis and neurological disease, predominantly in stroke and dementia.

The bullous pemphigoid blister develops on the skin area that tend to flex such as lower abdomen, upper thigh and armpits. Bullous Pemphigoid causes severe itch, tense bullae, annular lesions, post inflammatory pigmentation, blood stained blister fluids and urticaria-like red skin. Proper medication involved in overturning the immune system plays an important role in treatment of the disease.

The medical treatment of bullous pemphigoid involves ultra-potent, moderate steroids, pain relief medication, immunosuppressant medication and antibiotics & antiseptics for bacterial infections.

Request a sample of this report -

https://www.persistencemarketresearch.com/samples/17392

Bullous Pemphigoid treatment market: Drivers & Restraints

Rising geriatric population over the globe increase chances of occurrence of disease and thus the surge in treatment options. Common and non-expensive medication uses in the treatment of disease increases fuels the treatment market. Furthermore, various awareness programs by healthcare organizations and NGOs supports the proliferation of treatment market. Non-availability of healthcare facilities in various less developed regions of globe with high incidence rate of disease restricts the overall market to grow.

Increased mortality rate associated with disease is encouraging the treatment market for Bullous pemphigoid to grow. Increasing evidence of few controlled clinical trials in this area also promotes the market. The drugs used for treating immunobullous disorders is also classified into rapid and slow acting, topical and systemic, or immunosuppressant and anti-inflammatory. There are huge number of players in the treatment market which also intensifies the competition. Region specific players also have an overall impact over the market.

Geographically, the market for bullous pemphigoid treatment can be segmented into five regions, North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Studies demonstrate that Europe holds the largest market share for the treatment of the disease because of the high incidence rate such as 6 or 7 cases per 1 million persons per year and availability of healthcare facilities to every section of the region. This is followed by North America because of large number of healthcare providers and treatment facilities in the region. In addition to this, better technology and reimbursement scenario facilitates the market growth in these regions. The market in Asia Pacific and Middle East countries is also anticipated to show significant increase in the coming years because of government efforts in improving healthcare facilities and increasing awareness in the region about the disease and treatment options availability

Request a ToC of this report -

https://www.persistencemarketresearch.com/toc/17392

Some major key players of bullous pemphigoid treatment market are Pfizer Inc., Aqua Pharmaceuticals, Greenstone LLC, Sirius Laboratories, DUBLIN Pharmaceuticals, Teva Pharmaceuticals, Astellas Pharma India Pvt Ltd., Aegis Pharmaceuticals, Sun Pharmaceuticals and many more.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

USA – Canada Toll Free: 800-961-0353

Email: [email protected]

Web: http://www.persistencemarketresearch.com

0 notes